Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal Consta vs Oral Antipsychotics in Early Psychosis
NCT00246259Phase 4Completed
- Sponsor
- Janssen Ortho
- Start
- Oct 2004
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in schizophrenia, schizoaffective disorder and schizophreniform disorder (2 arms), sponsored by Janssen Ortho. Primary endpoints: Positive and Negative Syndrome Scale Total Score at 104 weeks, Time to Relapse at 104 weeks and 1 more. Started Oct 2004; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT00246259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246259.